BenchSci vs Schrödinger
Side-by-side comparison of AI visibility scores, market position, and capabilities
BenchSci is an AI-powered biomedical research intelligence platform used by 16 of the top 20 pharma companies; accelerates experiment design by analyzing millions of scientific papers and proprietary data to recommend validated reagents and.
About
BenchSci is a Toronto-based life sciences AI company founded in 2015 by Tom Leung, Elvis Wianda, Liran Belenzon, and David Chen. The company builds AI-powered research intelligence software that helps biomedical scientists — particularly at pharmaceutical and biotechnology companies — design better experiments faster, reduce failure rates, and avoid duplicating work that has already been done. BenchSci''s platform applies machine learning to analyze both published scientific literature (including open-access and licensed journal databases) and proprietary experimental data from its pharma clients, extracting structured information about reagent performance, experimental protocols, and biological targets to generate recommendations for researchers planning new experiments.
Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue up 54% YoY; $150M Novartis collaboration signed in early 2025.
About
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has developed the industry-leading molecular modeling suite used by academic researchers, biotech startups, and large pharmaceutical companies to predict molecular properties, optimize lead compounds, and design drugs with greater precision than traditional empirical approaches.\n\nSchrödinger's platform—spanning FEP+ (free energy perturbation), Glide docking, WaterMap, and machine learning-enhanced property prediction—is used by over 1,700 organizations across pharma, biotech, and materials science. In early 2025, the company signed a landmark $150 million upfront collaboration with Novartis for multi-target drug discovery with potential milestones exceeding $2.3 billion. Software revenue grew 54% year-over-year in Q3 2025 as pharmaceutical companies accelerated adoption of computational-first drug discovery. Schrödinger also operates a proprietary drug pipeline, with SGR-1505 (MALT1 inhibitor) in Phase 1 for B-cell malignancies.\n\nSchrödinger occupies a unique hybrid position—part software platform, part drug discovery company—and is a benchmark of the AI/physics-based drug discovery movement. The company is publicly traded (SDGR) and is recognized as an essential tool for the modern small-molecule drug discovery workflow.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.